EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study

Victor S Wang iD, Justin Kosman, Hsiangkuo Yuan, Clinton Lauritsen iD, Stephen Shrewsbury, Sheena K Aurora iD, Mary Hopkins, Stephen Silberstein

Headache: The Journal of Head and Face Pain · 2023

DOI: 10.1111/head.14636 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2023. Verfasst von Victor S Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Dihydroergotamine, Cardiovascular Diseases, Vasoconstrictor Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Impel Pharmaceuticals, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dihydroergotamine (DHE), like triptans, is contraindicated in patients with ischemic heart disease or coronary vasospasm. Its true safety, tolerability, and efficacy in patients with cardiovascular risk without ischemic heart disease or coronary vasospasm remain unclear.

Objectives

To assess the safety, tolerability, and effectiveness of repetitive intravenous DHE in patients with cardiovascular risk factors.

Methods

A single‐center, retrospective cohort study was conducted at the Jefferson Headache Center inpatient unit for refractory chronic migraine patients treated with our intravenous DHE protocol between January 1, 2019, and October 15, 2019. We evaluated tolerability and effectiveness outcomes based on atherosclerotic cardiovascular disease 10‐year calculated risk scores, stratified into low (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersDihydroergotamineCardiovascular DiseasesVasoconstrictor AgentsHumansRetrospective StudiesFemaleMaleMiddle AgedAdultHeart Disease Risk FactorsChronic DiseaseAdministration, IntravenousTreatment Outcome

Stichwörter der Autor:innen

chronic daily headachechronic migrainedihydroergotaminemigrainerefractory headache

Substanzen

DihydroergotamineVasoconstrictor Agents

Autor:innen und Institutionen

  • Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Thomas Jefferson University College of Population Health, Philadelphia, Pennsylvania, USA.
  • Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Impel Pharmaceuticals Inc., Seattle, Washington, USA.

ORCID-Profile: Victor S Wang, Clinton Lauritsen, Sheena K Aurora

Förderung

  • Impel Pharmaceuticals, Inc.

Zitieren

APA

Wang, V. S., Kosman, J., Yuan, H., Lauritsen, C., Shrewsbury, S., Aurora, S. K., Hopkins, M., & Silberstein, S. (2023). Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14636

Vancouver

Wang VS, Kosman J, Yuan H, Lauritsen C, Shrewsbury S, Aurora SK, et al. Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study. Headache: The Journal of Head and Face Pain. 2023. doi:10.1111/head.14636

BibTeX
@article{Wang2023,
  author = {Wang, Victor S and Kosman, Justin and Yuan, Hsiangkuo and Lauritsen, Clinton and Shrewsbury, Stephen and Aurora, Sheena K and Hopkins, Mary and Silberstein, Stephen},
  title = {Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  doi = {10.1111/head.14636}
}
Kostenlos starten →